Evidence supporting the use of: Tetrahydrocannabinol
For the health condition: Neuralgia and Neuritis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, has scientific evidence supporting its use in the management of certain types of neuropathic pain, which includes neuralgia and neuritis. Multiple randomized controlled trials and systematic reviews indicate that THC, either alone or in combination with cannabidiol (CBD), can reduce chronic neuropathic pain symptoms in some patients. The mechanism is thought to involve THC’s activity at CB1 and CB2 cannabinoid receptors in the central and peripheral nervous systems, which modulate pain signaling and inflammation.

Notably, clinical guidelines and meta-analyses (such as those published in JAMA, 2015, and by the National Academies of Sciences, 2017) conclude that there is moderate evidence for cannabinoids in the treatment of chronic neuropathic pain. However, the magnitude of benefit is generally modest and varies between individuals, and side effects (including cognitive impairment, dizziness, and psychiatric symptoms) are not uncommon.

While THC is not universally recommended as a first-line therapy for neuralgia or neuritis, its use is considered in cases where standard treatments fail or are not tolerated. Regulatory approvals and medical use guidelines differ by country. Overall, scientific validation exists but is limited by the quality and scale of available evidence, and ongoing research continues to clarify its role.

More about Tetrahydrocannabinol
More about Neuralgia and Neuritis

Products containing Tetrahydrocannabinol

We currently have no products on Vitabase that contain this ingredient.